{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T16:51:34Z","timestamp":1761238294779},"reference-count":0,"publisher":"Informa UK Limited","license":[{"start":{"date-parts":[[2016,5,1]],"date-time":"2016-05-01T00:00:00Z","timestamp":1462060800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/3.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["PPA"],"DOI":"10.2147\/ppa.s83946","type":"journal-article","created":{"date-parts":[[2016,5,15]],"date-time":"2016-05-15T19:47:15Z","timestamp":1463341635000},"page":"825","source":"Crossref","is-referenced-by-count":9,"title":["Patient perspectives on fluticasone–vilanterol versus other corticosteroid combination products for the treatment of asthma"],"prefix":"10.2147","author":[{"given":"Suzanne","family":"Bollmeier","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Theresa","family":"Prosser","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2016,5]]},"container-title":["Patient Preference and Adherence"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.dovepress.com\/getfile.php?fileID=30365","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2016,10,30]],"date-time":"2016-10-30T18:46:19Z","timestamp":1477853179000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.dovepress.com\/patient-perspectives-on-fluticasonendashvilanterol-versus-other-cortic-peer-reviewed-article-PPA"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,5]]},"references-count":0,"URL":"https:\/\/doi.org\/10.2147\/ppa.s83946","relation":{},"ISSN":["1177-889X"],"issn-type":[{"value":"1177-889X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,5]]}}}